Terms: = Liver cancer AND ARID1B, 6A3-5, 57492, ENSG00000049618, p250R, KIAA1235, ELD/OSA1, DAN15, BRIGHT, BAF250b AND Clinical Outcome
1 results:
1. Sorafenib may enhance antitumour efficacy in hepatocellular carcinoma patients by modulating the proportions and functions of natural killer cells.
Hu J; Wang E; Liu L; Wang Q; Xia D; Bai W; Tie J; Li X; Yuan J; Yang S; Jiang D; Shi J; Sun Y; Wang J; Zhang C; Niu J; Li K; He C; Guo W; Lv Y; Chen H; Yuan X; Yu T; Wang Z; Luo B; Han N; Zhu Y; Yin Z; Fan D; Zhang Z; Yang K; Han G
Invest New Drugs; 2020 Oct; 38(5):1247-1256. PubMed ID: 31832851
[TBL] [Abstract] [Full Text] [Related]
